Skip to content

Angong Jiangyawan

A randomized, double-blind, placebo controled, multi-center clinical trial for the treatment of hypertension 2, and the efficacy and safety of the Angong Jiangyawan

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-17012500
Enrollment
Unknown
Registered
2017-08-29
Start date
2017-09-01
Completion date
Unknown
Last updated
2017-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

secondary hypertension

Interventions

Control group:placebo
Experimental group:Angong Jiangyawan

Sponsors

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Criteria for the diagnosis of hypertension 2 in western medicine; 2. Conform to the syndrome differentiation of traditional Chinese medicine something KangCheng syndrome; 3. Between 18 and 75 years of age (including 18 and 75 years), gender is not limited; 4. using CCB and ARB or using CCB and ß-blocker. One of those two options is a one-month period of time and the blood pressure is not up to the mark, and the drug is not replaced during the trial and the dosage is not adjusted; 5. Signed the ICF.

Exclusion criteria

Exclusion criteria: 1. secondary hypertension,hypertension 1or 3 was diagnosed; 2. The use of more than 3 kinds of single-side drug depressor and the use of compound preparation of antihypertensive agents; 3. Cerebral vascular accident, transient ischemic attack, myocardial infarction or heart failure;Aortic aneurysm or an aneurysm;Definite angina, II degree atrioventricular block, sick sinus syndrome and other malignant or potential malignant arrhythmia in the last 6 months; 4. Severe retinopathy such as hemorrhage or exudate and disc edema; 5. To merge the liver (the AST, ALT and TBIL over the normal limit of 2 or more), the renal (Cr over the normal limit of 1 1/2 or above), and the hematopoietic system for severe primary diseases, psychopaths; 6. Diabetic blood glucose control is not good, fasting blood sugar is greater than 11.1 mol/l; 7. K >5.5mmol/L; 8. Day and night upside down life state, need often on the night shift; 9. Allergic or allergic to ingredients of this drug; 10. Pregnant or lactating women; 11. Other drug trials in the last three months.

Design outcomes

Primary

MeasureTime frame
The average sitting pressure is lower than the baseline;

Secondary

MeasureTime frame
Blood pressure success rate;Systolic Pressure Variation;The Chinese medicine certificate waits curative effect;Symptoms of a single symptom;quality of life score;

Countries

China

Contacts

Public ContactYuping Yan

Beijing tongrentang Co, LTD. Tongrentang Pharmacceutical Factory

yanyuping0@126.com+86 010 87632545

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026